2-Methylmescaline

2-Methylmescaline
Clinical data
Other names2-Me-M; 2-Methyl-3,4,5-trimethoxyphenethylamine; 3,4,5-Trimethoxy-2-methylphenethylamine
Drug classSerotonin receptor modulator
ATC code
  • None
Identifiers
  • 2-(3,4,5-trimethoxy-2-methylphenyl)ethanamine
PubChem CID
Chemical and physical data
FormulaC12H19NO3
Molar mass225.288 g·mol−1
3D model (JSmol)
  • CC1=C(C(=C(C=C1CCN)OC)OC)OC
  • InChI=1S/C12H19NO3/c1-8-9(5-6-13)7-10(14-2)12(16-4)11(8)15-3/h7H,5-6,13H2,1-4H3
  • Key:PCULFTFEHMIRBM-UHFFFAOYSA-N

2-Methylmescaline (2-Me-M), also known as 2-methyl-3,4,5-trimethoxyphenethylamine, is a serotonin receptor modulator of the phenethylamine and scaline families related to mescaline. It is the 2-methyl derivative of mescaline. The drug shows affinity for the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors (Ki = 525 nM, 1,640 nM, and 1,094 nM, respectively). These affinities were 5.7-fold, 2.8-fold, and 7.1-fold higher than those of mescaline, respectively. The drug is not known to have been tested in animals or humans. 2-Methylmescaline was first described in the scientific literature by Daniel Trachsel and colleagues in 2013. The source of the information cited by Trachsel and colleagues was personal communication with David E. Nichols in 2010. It is not a controlled substance in Canada as of 2025.

See also

References

  1. 1 2 3 4 5 6 7 Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. pp. 908–909. ISBN 978-3-03788-700-4. OCLC 858805226. Archived from the original on 13 November 2025. Retrieved 26 November 2025.{{cite book}}: CS1 maint: bot: original URL status unknown (link)
  2. ↑ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.